Beijing Balance Medical Technology Co Ltd
SSE:688198

Watchlist Manager
Beijing Balance Medical Technology Co Ltd Logo
Beijing Balance Medical Technology Co Ltd
SSE:688198
Watchlist
Price: 112.01 CNY 0.89% Market Closed
Market Cap: 15.4B CNY
Section:
 

Relative Value

The Relative Value of one Beijing Balance Medical Technology Co Ltd stock under the Base Case scenario is 81.62 CNY. Compared to the current market price of 112.01 CNY, Beijing Balance Medical Technology Co Ltd is Overvalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
81.62 CNY
Overvaluation 27%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

26.1
P/S
P/S
Price to Sales
26.1
vs History
93
vs Industry
24
Median 3Y
40.1
Median 5Y
49.2
Industry
8.2
Forward
24.3
More Details
85.7
P/E
P/E
Price to Earnings
85.7
vs History
90
vs Industry
1
Median 3Y
138.1
Median 5Y
158.4
Industry
24.2
Forward
79.9
More Details
71.2
P/OCF
P/OCF
Price to OCF
71.2
vs History
93
vs Industry
1
Median 3Y
120.5
Median 5Y
137.1
Industry
23
More Details
91.2
P/FCFE
P/FCFE
Price to FCFE
91.2
vs History
71
vs Industry
0
Median 3Y
98.1
Median 5Y
386.6
Industry
25.5
More Details
12.4
P/B
P/B
Price to Book Value
12.4
vs History
69
vs Industry
6
Median 3Y
13.2
Median 5Y
13.9
Industry
3.3
More Details
26.3
EV/S
EV/S
Enterprise Value to Sales
26.3
vs History
92
vs Industry
20
Median 3Y
39.1
Median 5Y
45.7
Industry
8.6
Forward
24.5
More Details
30.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
30.3
vs History
92
vs Industry
17
Median 3Y
43.7
Median 5Y
51.7
Industry
10.5
More Details
85.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
85.4
vs History
90
vs Industry
0
Median 3Y
160.4
Median 5Y
185.2
Industry
6.1
Forward
64.8
More Details
85.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
85.4
vs History
90
vs Industry
0
Median 3Y
160.4
Median 5Y
185.2
Industry
6.6
Forward
38.7
More Details
71.6
EV/OCF
EV/OCF
Enterprise Value to OCF
71.6
vs History
93
vs Industry
0
Median 3Y
116.9
Median 5Y
133.4
Industry
8.8
More Details
164.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
164.4
vs History
65
vs Industry
0
Median 3Y
176.8
Median 5Y
661.9
Industry
6.8
More Details
10.8
EV/IC
EV/IC
Enterprise Value to IC
10.8
vs History
95
vs Industry
14
Median 3Y
16.3
Median 5Y
25.1
Industry
5.7
More Details

Multiples Across Competitors

Competitors Multiples
Beijing Balance Medical Technology Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Beijing Balance Medical Technology Co Ltd
SSE:688198
15.5B CNY 26.1 85.7 85.4 85.4
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 256 368 717.6 -17 605 753.9 -17 276 635.9 -17 238 178.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 103 527.5 -162 089 -196 827.8 -194 581.7
US
Abbvie Inc
NYSE:ABBV
389B USD 6.5 165.7 16.1 22.8
US
Amgen Inc
NASDAQ:AMGN
175.4B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
150.4B USD 5.2 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.8B USD 10.1 32.1 23.5 24.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.7 -527.1 -574 -558.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.9B USD 5.9 18.3 17.5 19.9
AU
CSL Ltd
ASX:CSL
84.4B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD 16.4 1 204.9 162.5 197
P/E Multiple
Earnings Growth PEG
CN
Beijing Balance Medical Technology Co Ltd
SSE:688198
Average P/E: 196.1
85.7
33%
2.6
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 605 753.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 089 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
10%
1.8
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 204.9
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Beijing Balance Medical Technology Co Ltd
SSE:688198
Average EV/EBITDA: 43.5
85.4
45%
1.9
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 276 635.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 827.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
162.5
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Beijing Balance Medical Technology Co Ltd
SSE:688198
Average EV/EBIT: 49.5
85.4
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 238 178.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 581.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197
N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.